GenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner.

GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform.

These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.